Ryan C. Ungaro
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ryan C. Ungaro has a total of 818 co-authors. Here are the top co-authors by number of shared publications:
- Jean-Frederic Colombel
The Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, USA
44 shared publications Jean-Frederic Colombel
Dr Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai , New York, NY
14 shared publications- Manasi Agrawal
The Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, USA
13 shared publications - Bruce E. Sands
Dr. Henry D. Janowitz Division of Gastroenterology Icahn School of Medicine at Mount Sinai New York New York USA
10 shared publications - Judy H. Cho
Department of Pathology, Molecular, and Cell-Based Medicine, Icahn School of Medicine at Mount Sinai
9 shared publications Jean-Frédéric Colombel
The Dr Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai , New York, 10029, NY
7 shared publications
Latest Publications
- Open Access
- 24 April 2026
- Published by Oxford University Press (OUP) in Crohn's & Colitis 360
- Vol. 8 (2)
Prevalence, Age-Distribution, and Impact on Management of Acne in Patients on Upadacitinib for Inflammatory Bowel Disease: Insights from a Single-Center Survey
Background: Upadacitinib (UPA), an oral JAK1 inhibitor, has been associated with acne in up to 7% of patients with inflammatory bowel disease (IBD) in clinical trials. Emerging real-world evidence suggests the true prevalence may be higher, particularly among adolescents and young adults. This study evaluated the prevalence, age distribution, and impact of UPA-associated acne on treatment decisions in a real-world IBD cohort. Methods: A cross-sectional survey was conducted within a prospective IBD BioBank at a tertiary care center. All patients currently or previously treated with UPA (n = 110) were invited to complete a 22-item electronic survey assessing acne history before and after UPA initiation, acne severity, treatments used, awareness of acne as a side effect, and influence on medication management. Results: The survey was completed by 100 patients (91% response rate); 54% had Crohn’s disease and 46% ulcerative colitis. The median age was 23 years (IQR 18–35, range 7-66). Prior to UPA, 25% reported acne, predominantly mild. After starting UPA, 48% experienced new or worsening acne; 38% reported it as moderate, 29% as severe, and 46% sought dermatologic care. At time of survey (median 458 days), 52% continued to have acne, well-controlled in only ¼ with treatment; 5% had discontinued UPA due to acne. While 80% felt the benefits of UPA outweighed acne-related concerns, 7% disagreed—despite most achieving clinical remission. Acne was significantly less prevalent at the extremes of age, 50 (P = 0.003). Conclusion: Acne is a frequent and sometimes treatment-limiting side effect of UPA. Targeted counseling may support adherence.
- 24 April 2026
- Published by Oxford University Press (OUP) in Crohn's & Colitis 360
- Vol. 8 (2)
Open AccessPrevalence, Age-Distribution, and Impact on Management of Acne in Patients on Upadacitinib for Inflammatory Bowel Disease: Insights from a Single-Center Survey
Background: Upadacitinib (UPA), an oral JAK1 inhibitor, has been associated with acne in up to 7% of patients with inflammatory bowel disease (IBD) in clinical trials. Emerging real-world evidence suggests the true prevalence may be higher, particularly among adolescents and young adults. This study evaluated the prevalence, age distribution, and impact of UPA-associated acne on treatment decisions in a real-world IBD cohort. Methods: A cross-sectional survey was conducted within a prospective IBD BioBank at a tertiary care center. All patients currently or previously treated with UPA (n = 110) were invited to complete a 22-item electronic survey assessing acne history before and after UPA initiation, acne severity, treatments used, awareness of acne as a side effect, and influence on medication management. Results: The survey was completed by 100 patients (91% response rate); 54% had Crohn’s disease and 46% ulcerative colitis. The median age was 23 years (IQR 18–35, range 7-66). Prior to UPA, 25% reported acne, predominantly mild. After starting UPA, 48% experienced new or worsening acne; 38% reported it as moderate, 29% as severe, and 46% sought dermatologic care. At time of survey (median 458 days), 52% continued to have acne, well-controlled in only ¼ with treatment; 5% had discontinued UPA due to acne. While 80% felt the benefits of UPA outweighed acne-related concerns, 7% disagreed—despite most achieving clinical remission. Acne was significantly less prevalent at the extremes of age, 50 (P = 0.003). Conclusion: Acne is a frequent and sometimes treatment-limiting side effect of UPA. Targeted counseling may support adherence.
- 18 February 2026
- Published by Oxford University Press (OUP) in Inflammatory Bowel Diseases
Artificial intelligence enhances screening efficiency for inflammatory bowel disease clinical trials: a prospective study
Lay Summary: An LLM-based AI tool significantly improved identification of potentially eligible patients and screening efficiency for IBD clinical trials, outperforming physician referrals by screening electronic medical records and generating ranked candidate lists based on trial inclusion/exclusion criteria, thereby enhancing trial recruitment.
- 18 February 2026
- Published by Oxford University Press (OUP) in Inflammatory Bowel Diseases
Artificial intelligence enhances screening efficiency for inflammatory bowel disease clinical trials: a prospective study
Lay Summary: An LLM-based AI tool significantly improved identification of potentially eligible patients and screening efficiency for IBD clinical trials, outperforming physician referrals by screening electronic medical records and generating ranked candidate lists based on trial inclusion/exclusion criteria, thereby enhancing trial recruitment.
- Open Access
- 3 February 2026
- Vol. 8 (1)
Patients’ attitudes to disease prevention in inflammatory bowel disease: a US-based survey
Recent advances in biomarkers have identified at-risk cohorts for inflammatory bowel disease (IBD), and potential interception strategies to prevent disease onset are in progress. We sought to understand patient and family members’ views on IBD prevention, as they are key stakeholders in future adoption of prevention recommendations. A workgroup of patient advocacy organizations and researchers adapted a survey for completion by the IBD community residing in the United States. All responses were anonymous. Descriptive results, and comparisons, were undertaken of pooled responses. One thousand five hundred forty-five respondents completed the survey. Most respondents (93%, n = 1,421) would be interested in taking a test to predict their or their family’s risk of developing IBD in the future. Almost all respondents were interested in taking preventative treatment to prevent IBD; 40% expressed an unconditional interest in the treatment, but 59% reported it would be dependent on the risks and effectiveness of the treatment. Lifestyle measures were the most preferred option to prevent IBD. There was no significant difference in proportion of patients who were willing to take a test or prevention treatment based on relationship to IBD (have IBD, first-degree relative of someone who has IBD, or parent of someone with IBD). Most people affected by IBD in the United States agree with taking proactive measures to prevent IBD. A lifestyle intervention (diet, exercise) is favored over a pharmaceutical approach by these respondents. Relationship to IBD did not influence the magnitude of the agreement.
- 3 February 2026
- Vol. 8 (1)
Open AccessPatients’ attitudes to disease prevention in inflammatory bowel disease: a US-based survey
Recent advances in biomarkers have identified at-risk cohorts for inflammatory bowel disease (IBD), and potential interception strategies to prevent disease onset are in progress. We sought to understand patient and family members’ views on IBD prevention, as they are key stakeholders in future adoption of prevention recommendations. A workgroup of patient advocacy organizations and researchers adapted a survey for completion by the IBD community residing in the United States. All responses were anonymous. Descriptive results, and comparisons, were undertaken of pooled responses. One thousand five hundred forty-five respondents completed the survey. Most respondents (93%, n = 1,421) would be interested in taking a test to predict their or their family’s risk of developing IBD in the future. Almost all respondents were interested in taking preventative treatment to prevent IBD; 40% expressed an unconditional interest in the treatment, but 59% reported it would be dependent on the risks and effectiveness of the treatment. Lifestyle measures were the most preferred option to prevent IBD. There was no significant difference in proportion of patients who were willing to take a test or prevention treatment based on relationship to IBD (have IBD, first-degree relative of someone who has IBD, or parent of someone with IBD). Most people affected by IBD in the United States agree with taking proactive measures to prevent IBD. A lifestyle intervention (diet, exercise) is favored over a pharmaceutical approach by these respondents. Relationship to IBD did not influence the magnitude of the agreement.
- Open Access
- 14 January 2026
- Published by Springer Nature in Communications Medicine
- Vol. 6 (1)
Automating clinical phenotyping using natural language processing
Background: Real-world studies based on electronic health records often require manual chart review to derive patients’ clinical phenotypes, a labor-intensive task with limited scalability. Here, we developed and compared computable phenotyping based on rules using the spaCy framework and a Large Language Model (LLM), GPT-4, for sub-phenotyping of patients with Crohn’s disease, considering age at diagnosis and disease behavior. Methods: For our rule-based approach, we leveraged the spaCy framework and for the LLM-based approach, we used the GPT-4 model. The underlying data included 49,572 clinical notes and 2204 radiology reports from 584 Crohn’s disease patients. A test set of 280 clinical texts was labeled at sentence-level, in addition to patient-level ground truth data. The algorithms were evaluated based on their recall, precision, specificity values, and F1 scores. Results: Overall, we observe similar or better performance using GPT-4 compared to the rules. On a note-level, the F1 score is at least 0.90 for disease behavior and 0.82 for age at diagnosis, and on patient level at least 0.66 for disease behavior and 0.71 for age at diagnosis. Conclusions: To our knowledge, this is the first study to explore computable phenotyping algorithms based on clinical narrative text for these complex tasks, where prior inter-annotator agreements ranged from 0.54 to 0.98. There is no statistical evidence for a difference to the performance of human experts on this task. Our findings underline the potential of LLMs for computable phenotyping and may support large-scale cohort analyses from electronic health records and streamline chart review processes in the future.
- 14 January 2026
- Published by Springer Nature in Communications Medicine
- Vol. 6 (1)
Open AccessAutomating clinical phenotyping using natural language processing
Background: Real-world studies based on electronic health records often require manual chart review to derive patients’ clinical phenotypes, a labor-intensive task with limited scalability. Here, we developed and compared computable phenotyping based on rules using the spaCy framework and a Large Language Model (LLM), GPT-4, for sub-phenotyping of patients with Crohn’s disease, considering age at diagnosis and disease behavior. Methods: For our rule-based approach, we leveraged the spaCy framework and for the LLM-based approach, we used the GPT-4 model. The underlying data included 49,572 clinical notes and 2204 radiology reports from 584 Crohn’s disease patients. A test set of 280 clinical texts was labeled at sentence-level, in addition to patient-level ground truth data. The algorithms were evaluated based on their recall, precision, specificity values, and F1 scores. Results: Overall, we observe similar or better performance using GPT-4 compared to the rules. On a note-level, the F1 score is at least 0.90 for disease behavior and 0.82 for age at diagnosis, and on patient level at least 0.66 for disease behavior and 0.71 for age at diagnosis. Conclusions: To our knowledge, this is the first study to explore computable phenotyping algorithms based on clinical narrative text for these complex tasks, where prior inter-annotator agreements ranged from 0.54 to 0.98. There is no statistical evidence for a difference to the performance of human experts on this task. Our findings underline the potential of LLMs for computable phenotyping and may support large-scale cohort analyses from electronic health records and streamline chart review processes in the future.
- Open Access
- 3 November 2025
- Published by Oxford University Press (OUP) in JAMIA Open
- Vol. 8 (6)
The AIR·MS data platform for artificial intelligence in healthcare
Objective: To present the Artificial Intelligence-Ready Mount Sinai (AIR·MS) platform-unified access to diverse clinical datasets from the Mount Sinai Health System (MSHS), along with computational infrastructure for AI-driven research and demonstrate its utility with 3 research projects. Materials and Methods: AIR·MS integrates structured and unstructured data from multiple MSHS sources via the OMOP Common Data Model on an in-memory columnar database. Unstructured pathology and radiology data are integrated through metadata extracted from and linking the raw source data. Data access and analytics are supported from the HIPAA-compliant Azure cloud and the on-premises Minerva High-Performance Computing (HPC) environment. Results: AIR·MS provides access to structured electronic health records, clinical notes, and metadata for pathology and radiology images, covering over 12M patients. The platform enables interactive cohort building and AI model training. Experimentation with complex cohort queries confirm a high system performance. Three use cases demonstrate, risk-factor discovery, and federated cardiovascular risk modeling. Discussion: AIR·MS demonstrates how clinical data and infrastructure can be integrated to support large-scale AI-based research. The platform’s performance, scale, and cross-institutional design position it as a model for similar initiatives. Conclusion: AIR·MS provides a scalable, secure, and collaborative platform for AI-enabled healthcare research on multimodal clinical data.
- 3 November 2025
- Published by Oxford University Press (OUP) in JAMIA Open
- Vol. 8 (6)
Open AccessThe AIR·MS data platform for artificial intelligence in healthcare
Objective: To present the Artificial Intelligence-Ready Mount Sinai (AIR·MS) platform-unified access to diverse clinical datasets from the Mount Sinai Health System (MSHS), along with computational infrastructure for AI-driven research and demonstrate its utility with 3 research projects. Materials and Methods: AIR·MS integrates structured and unstructured data from multiple MSHS sources via the OMOP Common Data Model on an in-memory columnar database. Unstructured pathology and radiology data are integrated through metadata extracted from and linking the raw source data. Data access and analytics are supported from the HIPAA-compliant Azure cloud and the on-premises Minerva High-Performance Computing (HPC) environment. Results: AIR·MS provides access to structured electronic health records, clinical notes, and metadata for pathology and radiology images, covering over 12M patients. The platform enables interactive cohort building and AI model training. Experimentation with complex cohort queries confirm a high system performance. Three use cases demonstrate, risk-factor discovery, and federated cardiovascular risk modeling. Discussion: AIR·MS demonstrates how clinical data and infrastructure can be integrated to support large-scale AI-based research. The platform’s performance, scale, and cross-institutional design position it as a model for similar initiatives. Conclusion: AIR·MS provides a scalable, secure, and collaborative platform for AI-enabled healthcare research on multimodal clinical data.
- 1 November 2025
- Published by Oxford University Press (OUP) in Journal of Crohn's and Colitis
- Vol. 19 (11)
Efficacy of 5-aminosalicylic acid continuation versus discontinuation in patients with ulcerative colitis escalated to advanced therapy: a systematic review and meta-analysis of adjusted effect estimates
Background and Aims: The benefit of continuing 5-aminosalicylates (5-ASA) in patients with ulcerative colitis (UC) escalated to advanced therapies remains uncertain. We conducted a systematic review and meta-analysis to evaluate the efficacy and safety of 5-ASA continuation vs discontinuation in this population. Methods: We systematically searched the PubMed, Embase, and Cochrane databases for studies comparing 5-ASA continuation vs discontinuation in adult patients with UC escalated to advanced therapies. Adjusted effect estimates were pooled using random-effects models. Results: The meta-analysis comprised nine observational cohorts and two studies presenting post-hoc analyses from eight clinical trials. We included 11 487 patients, with 9105 assigned to 5-ASA continuation and 2382 to 5-ASA discontinuation. Compared to discontinuation, 5-ASA continuation was associated with decreased odds of achieving clinical remission (adjusted odds ratio [aOR] 0.72; 95% CI 0.52-0.99; I2 = 0%). There were no significant differences between groups for corticosteroid-free clinical remission (aOR 0.71; 95% CI 0.41-1.23; I2 = 0%), clinical response (aOR 0.94; 95% CI 0.69-1.28; I2 = 0%), endoscopic healing (OR 1.00; 95% CI 0.71-1.41; I2 = 54.6%), and biochemical remission (aOR 1.13; 95% CI 0.76-1.68; I2 = 31%). In time-to-event analyses, no significant differences were found between groups for UC-related hospitalization (adjusted hazard ratio [aHR] 0.99; 95% CI 0.86-1.13; I2 = 0%), UC-related surgery (aHR 1.02; 95% CI 0.80-1.29; I2 = 13%), new corticosteroid prescription (aHR 0.97; 95% CI 0.88-1.07; I2 = 0%), composite adverse events (aHR 0.96; 95% CI 0.87-1.06; I2 = 0%), and loss of response (aHR 0.92; 95% CI 0.75-1.12; P = .39; I2 = 61%). Conclusion: In patients with UC escalated to advanced therapies, 5-ASA continuation was associated with decreased odds of achieving clinical remission compared to discontinuation, with no significant differences observed for secondary efficacy or safety endpoints.
- 1 November 2025
- Published by Oxford University Press (OUP) in Journal of Crohn's and Colitis
- Vol. 19 (11)
Efficacy of 5-aminosalicylic acid continuation versus discontinuation in patients with ulcerative colitis escalated to advanced therapy: a systematic review and meta-analysis of adjusted effect estimates
Background and Aims: The benefit of continuing 5-aminosalicylates (5-ASA) in patients with ulcerative colitis (UC) escalated to advanced therapies remains uncertain. We conducted a systematic review and meta-analysis to evaluate the efficacy and safety of 5-ASA continuation vs discontinuation in this population. Methods: We systematically searched the PubMed, Embase, and Cochrane databases for studies comparing 5-ASA continuation vs discontinuation in adult patients with UC escalated to advanced therapies. Adjusted effect estimates were pooled using random-effects models. Results: The meta-analysis comprised nine observational cohorts and two studies presenting post-hoc analyses from eight clinical trials. We included 11 487 patients, with 9105 assigned to 5-ASA continuation and 2382 to 5-ASA discontinuation. Compared to discontinuation, 5-ASA continuation was associated with decreased odds of achieving clinical remission (adjusted odds ratio [aOR] 0.72; 95% CI 0.52-0.99; I2 = 0%). There were no significant differences between groups for corticosteroid-free clinical remission (aOR 0.71; 95% CI 0.41-1.23; I2 = 0%), clinical response (aOR 0.94; 95% CI 0.69-1.28; I2 = 0%), endoscopic healing (OR 1.00; 95% CI 0.71-1.41; I2 = 54.6%), and biochemical remission (aOR 1.13; 95% CI 0.76-1.68; I2 = 31%). In time-to-event analyses, no significant differences were found between groups for UC-related hospitalization (adjusted hazard ratio [aHR] 0.99; 95% CI 0.86-1.13; I2 = 0%), UC-related surgery (aHR 1.02; 95% CI 0.80-1.29; I2 = 13%), new corticosteroid prescription (aHR 0.97; 95% CI 0.88-1.07; I2 = 0%), composite adverse events (aHR 0.96; 95% CI 0.87-1.06; I2 = 0%), and loss of response (aHR 0.92; 95% CI 0.75-1.12; P = .39; I2 = 61%). Conclusion: In patients with UC escalated to advanced therapies, 5-ASA continuation was associated with decreased odds of achieving clinical remission compared to discontinuation, with no significant differences observed for secondary efficacy or safety endpoints.
- Open Access
- 31 October 2025
- Published by Korean Association for the Study of Intestinal Diseases in Intestinal Research
- Vol. 23 (4) , 512-523
Knowledge and acceptability of the Lémann Index as a tool to measure disease progression and bowel damage in Crohn’s disease: results from an international survey
Background/Aims: Crohn’s disease (CD) progresses to structural bowel damage (SBD). The Lémann Index (LI) captures stricture extent/severity, penetrating disease and surgery as a SBD score, and is earmarked for future CD modification trials. Understanding knowledge gaps and perceived barriers is critical to wider adoption. Methods: A multinational, cross-sectional study was distributed through a survey link (REDCap, Research Electronic Data Capture) to gastrointestinal professional societies with snowball sampling using 23 questionnaire items in 5 sections to determine SBD and LI knowledge, and LI acceptability. Factors associated with acceptability and perception were evaluated. Results: Of the 107 respondents, 49 (45.8%) were female; 87 (81.3%) were from Europe. Most were inflammatory bowel disease specialists (n = 80, 74.8%) or general gastroenterologists (n = 22, 20.6%), managing > 40 CD patients per month (n = 35, 32.7%). A total of 98 (91.6%) knew about SBD; “very important” rating for clinical trials and clinical practice was 56.1% and 41.4%, respectively. A 39.3% describe LI scoring as “very difficult” or “difficult”; 33.6% reported “significant” or “a lot” of effort. Acceptability (composite scores of > 36) were significantly associated with respondents who had received LI training (P<0.001). Automated methods, intestinal ultrasound and evidence of benefit would encourage LI use in clinical trials, while additional time and automated methods would promote use in clinical practice. The top 3 perceived adoption barriers were: lack of time (60.7%), limited automated methods (47.7%) and need for dedicated radiologists (38.3%). Conclusions: Most respondents had baseline knowledge of SBD. The LI was perceived as important for advancing future CD research and care. More training and automation will facilitate LI adoption.
- 31 October 2025
- Published by Korean Association for the Study of Intestinal Diseases in Intestinal Research
- Vol. 23 (4) , 512-523
Open AccessKnowledge and acceptability of the Lémann Index as a tool to measure disease progression and bowel damage in Crohn’s disease: results from an international survey
Background/Aims: Crohn’s disease (CD) progresses to structural bowel damage (SBD). The Lémann Index (LI) captures stricture extent/severity, penetrating disease and surgery as a SBD score, and is earmarked for future CD modification trials. Understanding knowledge gaps and perceived barriers is critical to wider adoption. Methods: A multinational, cross-sectional study was distributed through a survey link (REDCap, Research Electronic Data Capture) to gastrointestinal professional societies with snowball sampling using 23 questionnaire items in 5 sections to determine SBD and LI knowledge, and LI acceptability. Factors associated with acceptability and perception were evaluated. Results: Of the 107 respondents, 49 (45.8%) were female; 87 (81.3%) were from Europe. Most were inflammatory bowel disease specialists (n = 80, 74.8%) or general gastroenterologists (n = 22, 20.6%), managing > 40 CD patients per month (n = 35, 32.7%). A total of 98 (91.6%) knew about SBD; “very important” rating for clinical trials and clinical practice was 56.1% and 41.4%, respectively. A 39.3% describe LI scoring as “very difficult” or “difficult”; 33.6% reported “significant” or “a lot” of effort. Acceptability (composite scores of > 36) were significantly associated with respondents who had received LI training (P<0.001). Automated methods, intestinal ultrasound and evidence of benefit would encourage LI use in clinical trials, while additional time and automated methods would promote use in clinical practice. The top 3 perceived adoption barriers were: lack of time (60.7%), limited automated methods (47.7%) and need for dedicated radiologists (38.3%). Conclusions: Most respondents had baseline knowledge of SBD. The LI was perceived as important for advancing future CD research and care. More training and automation will facilitate LI adoption.
- 8 October 2025
- Published by Oxford University Press (OUP) in Journal of Crohn's and Colitis
- Vol. 19 (10)
Disease duration impacts intestinal gene expression profiles in Crohn’s disease but not in ulcerative colitis
Background: Disease duration is associated with lower treatment response and accrual of bowel damage in Crohn’s disease (CD), but not in ulcerative colitis (UC). We aimed to understand intestinal transcriptomic changes associated with disease duration in CD and UC. Methods: We analyzed intestinal tissue RNA sequencing data from two independent prospective cohorts of CD and UC patients, the Mount Sinai Crohn’s and Colitis Registry (MSCCR; nCD = 498, nUC = 421), and the Study of a Prospective Adult Research Cohort with Inflammatory Bowel Disease (SPARC IBD; nCD = 777, nUC = 440). We conducted differential expression analysis and subsequent pathway analyses of significantly up- or down-regulated genes, and examined cell type-specific expression of significant genes and pathways in ileal single-cell RNA sequencing data from CD patients (n = 18). We then assessed the association of significant pathways with treatment response in an infliximab-treated CD cohort. Results: Significantly more genes were differentially expressed with increasing disease duration in CD compared to UC in both cohorts (MSCCR: nCD = 1472, nUC = 227; SPARC: nCD = 1248, nUC = 25; q-value < 0.05). A shared gene signature with 263 down- and 135 up-regulated genes in longer standing disease was identified. Pathway analyses revealed significant enrichment in pathways related to oxidative phosphorylation, mitochondrial dysfunction, cholesterol biosynthesis, liver X receptor/retinoid X receptor (LXR/RXR) activation, and protein modifications. Pre-treatment intestinal gene expression of four disease duration-related pathways were associated with non-response to infliximab. Conclusion: Disease duration influences intestinal gene expression in CD but significantly less so in UC. The identified pathways and genes may inform development of differing biomarkers and treatment strategies in shorter versus longer standing CD.
- 8 October 2025
- Published by Oxford University Press (OUP) in Journal of Crohn's and Colitis
- Vol. 19 (10)
Disease duration impacts intestinal gene expression profiles in Crohn’s disease but not in ulcerative colitis
Background: Disease duration is associated with lower treatment response and accrual of bowel damage in Crohn’s disease (CD), but not in ulcerative colitis (UC). We aimed to understand intestinal transcriptomic changes associated with disease duration in CD and UC. Methods: We analyzed intestinal tissue RNA sequencing data from two independent prospective cohorts of CD and UC patients, the Mount Sinai Crohn’s and Colitis Registry (MSCCR; nCD = 498, nUC = 421), and the Study of a Prospective Adult Research Cohort with Inflammatory Bowel Disease (SPARC IBD; nCD = 777, nUC = 440). We conducted differential expression analysis and subsequent pathway analyses of significantly up- or down-regulated genes, and examined cell type-specific expression of significant genes and pathways in ileal single-cell RNA sequencing data from CD patients (n = 18). We then assessed the association of significant pathways with treatment response in an infliximab-treated CD cohort. Results: Significantly more genes were differentially expressed with increasing disease duration in CD compared to UC in both cohorts (MSCCR: nCD = 1472, nUC = 227; SPARC: nCD = 1248, nUC = 25; q-value < 0.05). A shared gene signature with 263 down- and 135 up-regulated genes in longer standing disease was identified. Pathway analyses revealed significant enrichment in pathways related to oxidative phosphorylation, mitochondrial dysfunction, cholesterol biosynthesis, liver X receptor/retinoid X receptor (LXR/RXR) activation, and protein modifications. Pre-treatment intestinal gene expression of four disease duration-related pathways were associated with non-response to infliximab. Conclusion: Disease duration influences intestinal gene expression in CD but significantly less so in UC. The identified pathways and genes may inform development of differing biomarkers and treatment strategies in shorter versus longer standing CD.
- 24 September 2025
- Published by Oxford University Press (OUP) in Inflammatory Bowel Diseases
- Vol. 31 (Supplement) , S61-S70
How Should an IBD Prevention Trial Be Designed?
Background: Advances in understanding disease pathogenesis have revealed a preclinical phase of inflammatory bowel disease (IBD), offering a potential window for preventive measures. There is growing interest in trials to prevent IBD in at-risk individuals. However, there is limited guidance on how to set up prevention trials in IBD. This review aims to outline key considerations for designing an IBD prevention trial. Methods: We conducted a review of the literature, gaining insight from prevention trials in other immune-mediated inflammatory diseases (IMIDs). We focused on considerations to set up a secondary prevention trial regarding design, risk stratification and selection strategies, inclusion and exclusion criteria, endpoints, and ethical considerations. Results: Across IMIDs in which features predictive of future risk have been identified, trials have leveraged well-characterized at-risk cohorts, biomarkers for disease prediction, and feasible interventions. Key elements to consider include (1) identification and longitudinal monitoring of at-risk individuals based on biomarkers, (2) clear definitions of inclusion and exclusion criteria distinguishing a primary prevention trial to prevent disease in at-risk individuals from a secondary prevention trial in individuals with signs of subclinical disease, (3) use of time-to-event endpoints, (4) risk-benefit balancing in intervention choice, and (5) engagement of at-risk individuals. In IBD, analogous strategies are emerging and first-degree relatives stand out as a group for screening. Significant challenges remain in defining risk thresholds, optimizing endpoints, and selected interventions. Conclusion: Prevention trials in IBD hold promise but require careful design informed by experiences from other IMIDs. Central to this effort are the development of validated predictive tools, ethically appropriate interventions, and international collaboration to assemble well-powered at-risk cohorts.
- 24 September 2025
- Published by Oxford University Press (OUP) in Inflammatory Bowel Diseases
- Vol. 31 (Supplement) , S61-S70
How Should an IBD Prevention Trial Be Designed?
Background: Advances in understanding disease pathogenesis have revealed a preclinical phase of inflammatory bowel disease (IBD), offering a potential window for preventive measures. There is growing interest in trials to prevent IBD in at-risk individuals. However, there is limited guidance on how to set up prevention trials in IBD. This review aims to outline key considerations for designing an IBD prevention trial. Methods: We conducted a review of the literature, gaining insight from prevention trials in other immune-mediated inflammatory diseases (IMIDs). We focused on considerations to set up a secondary prevention trial regarding design, risk stratification and selection strategies, inclusion and exclusion criteria, endpoints, and ethical considerations. Results: Across IMIDs in which features predictive of future risk have been identified, trials have leveraged well-characterized at-risk cohorts, biomarkers for disease prediction, and feasible interventions. Key elements to consider include (1) identification and longitudinal monitoring of at-risk individuals based on biomarkers, (2) clear definitions of inclusion and exclusion criteria distinguishing a primary prevention trial to prevent disease in at-risk individuals from a secondary prevention trial in individuals with signs of subclinical disease, (3) use of time-to-event endpoints, (4) risk-benefit balancing in intervention choice, and (5) engagement of at-risk individuals. In IBD, analogous strategies are emerging and first-degree relatives stand out as a group for screening. Significant challenges remain in defining risk thresholds, optimizing endpoints, and selected interventions. Conclusion: Prevention trials in IBD hold promise but require careful design informed by experiences from other IMIDs. Central to this effort are the development of validated predictive tools, ethically appropriate interventions, and international collaboration to assemble well-powered at-risk cohorts.